Insilico Medicine
2 Intel
Insilico Medicine is a clinical-stage AI-driven biotechnology company founded in 2014 by Alex Zhavoronkov and Alex Aliper, focused on using generative AI to accelerate drug discovery. Its Pharma.AI platform has produced drug candidates including one that reached Phase II trials for idiopathic pulmonary fibrosis, and the company has signed major pharmaceutical partnerships, including a multibillion-dollar deal with Eli Lilly. It has been covered extensively by outlets such as MIT Technology Review and Nature, and has its own Wikipedia entry.
Is this you? Sign in with X to claim this profile.
Intel
Insilico's TNIK inhibitor ISM001-055, designed with generative AI, showed a dose-dependent lung-function improvement and good tolerability in a 71-patient Phase IIa trial for pulmonary fibrosis.
A Phase 2a analysis of 42 pulmonary-fibrosis patients found lower predicted biological age across six proteomic clocks after rentosertib treatment; the result is an exploratory biomarker finding, not proof that the drug reverses aging.